DXS has announced the expansion of its product development team in response to a rise in demand for its cancer diagnostic kits in 2008.
The company has increased its number of research and development staff in the final quarter of the year from four at the start of the year to eight, and plans to recruit a further five more product development scientists in the next month.
Dr Simon Flint joined DXS from the University of Sussex and brought with him a background in post-doctoral academic research in molecular biology and biochemical techniques specialising in translation initiation and antibiotic biosynthesis.
Dr Sarah Gray started in October with a PhD in Molecular Biology from the Royal College of Surgeons in Ireland.
Gray has a wealth of research experience and specialises in DNA extraction and PCR techniques.
In November Ian Riley and Dr Elloise Garside joined the company.
Ian has 11 years of experience at Astrazeneca, focusing on DNA sequencing and real-time PCR methods within the Clinical Genotyping Group.
Elloise joined from the Manchester Interdisciplinary Biocentre at the University of Manchester where she was a post-doctoral research associate.
Prior to that Elloise worked as a medical writer at Pyxis Medical Communications.
Rachael Carters worked as a member of the DXS service team during her industrial placement year as part of a BSC in Biology at the University of Manchester.
Responsible for the development of new assays and project work comparing DXS's Scorpions real-time PCR technology with other molecular beacons, Carters's aptitude for the role was rewarded when she was offered a permanent position in product development after she graduated in July 2008.
